Skip to main content
Log in

Bacteria-Triggered Reactive Arthritis

Implications for Antibacterial Treatment

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Reactive arthritis (ReA) is definitely caused by an infection. Several observations suggest that the triggering microbe may persist in the tissues of the patient for a prolonged time. The obvious conclusion is to consider antibacterial treatment. In two instances antibacterial agents are of definite value: in the primary and secondary prevention of rheumatic fever and for early eradication of Borrelia burgdorferi in order to prevent development of the arthritis associated with Lyme disease. Altogether, clinical and experimental data exist to indicate that if antibacterial treatment of ReA can be started very early during the pathogenetic process, the disease can be prevented or the prognosis improved. In fully developed ReA, the value of antibacterial agents is less certain. All available evidence indicates that short term antibacterial treatment has no effect on the prognosis and final outcome of ReA, and the results with long term administration of anti-bacterials are also overall poor. In some instances sulfasalazine appears useful, rather as a result of its antirheumatic effect or influence on an underlying inflammatory bowel disease than its action as an antibacterial agent. Tetracyclines have also been found to have an effect on ReA, but again, this is probably due to their anti-inflammatory action rather than any antibacterial effect.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Toivanen P, Toivanen A. Two forms of reactive arthritis? Ann Rheum Dis 1999; 58: 737–41

    Article  PubMed  CAS  Google Scholar 

  2. Toivanen A, Toivanen P. Aetiopathogenesis of reactive arthritis. Rheumatol Europe 1995; 24: 5–8

    Google Scholar 

  3. Lahesmaa-Rantala R, Granfors K, Isomäki H, et al. Yersinia-specific immune complexes in the synovial fluid of patients with Yersinia-triggered reactive arthritis. Ann Rheum Dis 1987; 46: 510–4

    Article  PubMed  CAS  Google Scholar 

  4. Merilahti-Palo R, Söderström K-O, Lahesmaa-Rantala R, et al. Bacterial antigens in synovial biopsy specimens in yersinia-triggered reactive arthritis. Ann Rheum Dis 1991; 50: 87–90

    Article  PubMed  CAS  Google Scholar 

  5. Granfors K, Jalkanen S, von Essen R, et al. Yersinia antigens in synovial-fluid cells from patients with reactive arthritis. N Engl J Med 1989; 320: 216–21

    Article  PubMed  CAS  Google Scholar 

  6. Gérard HC, Branigan PJ, Schumacher Jr HR, et al. Synovial Chlamydia trachomatis in patients with reactive arthritis/ Reiter’s syndrome are viable but show aberrant gene expression. J Rheumatol 1998; 25: 734–42

    PubMed  Google Scholar 

  7. Hughes RA, Keat AC. Reiters syndrome and reactive arthritis: a current view. Semin Arthritis Rheum 1994; 24: 190–210

    Article  PubMed  CAS  Google Scholar 

  8. Hammer M, Nettelnbreker E, Hopf S, et al. Chlamydial rRNA in the joints of patients with chlamydia-induced arthritis and undifferentiated arthritis. Clin Exp Rheumatol 1992; 10: 63–6

    PubMed  CAS  Google Scholar 

  9. Vilppula AH, Yli-Kerttula UI, Ahlroos AK, et al. Chlamydial isolations and serology in Reiter’s syndrome. Scand J Rheumatol 1981; 10: 181–5

    Article  PubMed  CAS  Google Scholar 

  10. Schachter J, Barnes MG, Jones JP, et al. Isolation of bedsoniae from the joints of patients with Reiters syndrome. Proc Soc Exp Biol Med 1996; 122: 283–5

    Google Scholar 

  11. Nikkari S, Rantakokko K, Ekman P, et al. Salmonella-triggered reactive arthritis: use of polymerase chain reaction, immuno-cytochemical staining, and gas chromatography-mass spectrometry in the detection of bacterial components from synovial fluid. Arthritis Rheum 1999; 42: 84–9

    Article  PubMed  CAS  Google Scholar 

  12. Ekman P, Nikkari S, Putto-Laurila A, et al. Detection of Salmonella infantis in synovial fluid cells of a patient with reactive arthritis. J Rheumatol 1999; 26: 2485–8

    PubMed  CAS  Google Scholar 

  13. Toivanen A, Granfors K, Lahesmaa-Rantala R, et al. Pathogenesis of Yersinia-triggered reactive arthritis: immunological, microbiological and clinical aspects. Immunol Rev 1985; 86: 47–70

    Article  PubMed  CAS  Google Scholar 

  14. Hoogkamp-Korstanje JAA, de Koning J, Heesemann J. Persistence of Yersinia enterocolitica in man. Infection 1988; 16: 81–5

    Article  PubMed  CAS  Google Scholar 

  15. Weyand CM, Goronzy JJ. Clinically silent infections in patients with oligoarthritis: results of a prospective study. Ann Rheum Dis 1992; 51: 253–8

    Article  PubMed  CAS  Google Scholar 

  16. Sairanen E, Paronen I, Mähönen H. Reiter’s syndrome: a follow-up study. Acta Med Scand 1969; 185: 57–63

    Article  PubMed  CAS  Google Scholar 

  17. Kvien TK, Glennås A, Melby K, et al. The natural history of reactive arthritis. Rheumatol Europe 1995; 24: 15–9

    Google Scholar 

  18. Leirisalo-Repo M, Suoranta H. Ten-year follow-up study of patients with Yersinia arthritis. Arthritis Rheum 1988; 31: 533–7

    Article  PubMed  CAS  Google Scholar 

  19. Leirisalo-Repo M, Helenius P, Hannu T, et al. Long term prognosis of reactive salmonella arthritis. Ann Rheum Dis 1997; 56: 516–20

    Article  PubMed  CAS  Google Scholar 

  20. Mielants H, Veys EM. The gut and reactive arthritis. Rheumatol Europe 1995; 24: 9–11

    Google Scholar 

  21. Yli-Kerttula T, Möttönen T, Toivanen A. Different course of reactive arthritis in two HLA-B27 positive brothers with fatal outcome in one. J Rheumatol 1997; 24: 2047–50

    PubMed  CAS  Google Scholar 

  22. Konttinen YT, Nordström DC, Bergroth V, et al. Occurrence of different ensuing triggering infections preceding reactive arthritis: a follow up study. BMJ 1988; 296: 1644–5

    Article  PubMed  CAS  Google Scholar 

  23. Jansen TL, Janssen M, van Riel PLCM. Acute rheumatic fever or post-streptococcal reactive arthritis: a clinical problem revisited. Br J Rheumatol 1998; 37: 335–40

    Article  PubMed  CAS  Google Scholar 

  24. Jansen TL, Janssen M, Traksel R, et al. A clinical and serological comparison of group A versus non-group A streptococcal reactive arthritis and throat culture negative cases of post-streptococcal reactive arthritis. Ann Rheum Dis 1999; 58: 410–4

    Article  PubMed  CAS  Google Scholar 

  25. Ahmed S, Ayoub EM, Scornik JC, et al. Poststreptococcal reactive arthritis: clinical characteristics and association with HLA-DR alleles. Arthritis Rheum 1998; 41: 1096–102

    Article  PubMed  CAS  Google Scholar 

  26. Mason T, Fisher M, Kujala G. Acute rheumatic fever in West Virginia: not just a disease of children. Arch Intern Med 1991; 151: 133–6

    Article  PubMed  CAS  Google Scholar 

  27. Amigo M-C, Martínez-Lavín M, Reyes PA. Acute rheumatic fever. Rheum Dis Clin North Am 1993; 19: 333–50

    PubMed  CAS  Google Scholar 

  28. Feuer J, Spiera H. Acute rheumatic fever in adults: a resurgence in the Hasidic Jewish community. J Rheumatol 1997; 24: 337–40

    PubMed  CAS  Google Scholar 

  29. Bisno AL. Group a streptococcal infections and acute rheumatic fever. N Engl J Med 1991; 325: 783–93

    Article  PubMed  CAS  Google Scholar 

  30. Lue HC, Wu MH, Wang JK, et al. Long-term outcome of patients with rheumatic fever receiving benzathine penicillin G prophylaxis every three weeks versus every four weeks. J Pediatr 1994; 125: 812–6

    Article  PubMed  CAS  Google Scholar 

  31. Jansen TL, Janssen M, de Jong AJ, et al. Post-streptococcal reactive arthritis: a clinical and serological description, revealing its distinction from acute rheumatic fever. J Intern Med 1999; 245: 261–7

    Article  PubMed  CAS  Google Scholar 

  32. Magid D, Schwartz B, Graft J, et al. Prevention of Lyme disease after tick bites. N Engl J Med 1992; 327: 534–41

    Article  PubMed  CAS  Google Scholar 

  33. Weber K, Pfister H-W. Clinical management of Lyme borreliosis. Lancet 1994; 343: 1017–20

    Article  PubMed  CAS  Google Scholar 

  34. Weyand CM, Goronzy JJ. Immune responses to Borrelia burgdorferi in patients with reactive arthritis. Arthritis Rheum 1989; 32: 1057–64

    Article  PubMed  CAS  Google Scholar 

  35. Gross DM, Forsthuber T, Tary-Lehman M, et al. Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science 1998; 281: 703–6

    Article  PubMed  CAS  Google Scholar 

  36. Preac-Mursic V, Weber K, Pfister HW, et al. Survival of Borrelia burgdorferi in antibiotically treated patients with Lyme borreliosis. Infection 1989; 17: 355–9

    Article  PubMed  CAS  Google Scholar 

  37. Steere AC, Dwyer E, Winchester R. Association of chronic Lyme arthritis with HLA-DR4 and HLA-DR2 alleles. N Engl J Med 1990; 323: 219–23

    Article  PubMed  CAS  Google Scholar 

  38. Hoogkamp-Korstanje JAA, de Koning J, Heesemann J, et al. Influence of antibiotics on IgA and IgG response and persistence of Yersinia enterocolitica in patients with Yersinia-associated spondylarthropathy. Infection 1992; 20: 53–7

    Article  PubMed  CAS  Google Scholar 

  39. Frydén A, Bengtsson A, Foberg U, et al. Early antibiotic treatment of reactive arthritis associated with enteric infections: clinical and serological study. BMJ 1990; 301: 1299–302

    Article  PubMed  Google Scholar 

  40. Locht H, Kihlström E, Lindström FD. Reactive arthritis after Salmonella among medical doctors: study of an outbreak. J Rheumatol 1993; 20: 845–8

    PubMed  CAS  Google Scholar 

  41. Mattila L, Leirisalo-Repo M, Pelkonen P, et al. Reactive arthritis following an outbreak of Salmonella bovismorbificans infection. J Infection 1998; 36: 289–95

    Article  CAS  Google Scholar 

  42. Popert AJ, Gill AJ, Laird SM. A prospective study of Reiter’s syndrome: an interim report on the first 82 cases. Br J Vener Dis 1964; 40: 160–5

    PubMed  CAS  Google Scholar 

  43. Bardin T, Schumacher HR. Should we treat postvenereal Reiters syndrome by antibiotics? J Rheumatol 1991; 18: 1780–2

    PubMed  CAS  Google Scholar 

  44. Bardin T, Enel C, Cornells F, et al. Antibiotic treatment of venereal disease and Reiter’s syndrome in a Greenland population. Arthritis Rheum 1992; 35: 190–4

    Article  PubMed  CAS  Google Scholar 

  45. Panayi GS, Clark B. Minocycline in the treatment of patients with Reiter’s syndrome. Clin Exp Rheumatol 1989; 7: 100–1

    PubMed  CAS  Google Scholar 

  46. Lauhio A, Leirisalo-Repo M, Lähdevirta J, et al. Double-blind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis, with special reference to Chlamydia arthritis. Arthritis Rheum 1991; 34: 6–14

    Article  PubMed  CAS  Google Scholar 

  47. Lauhio A, Sorsa T, Lindy O, et al. The anticollagenolytic potential of lymecycline in the long-term treatment of reactive arthritis. Arthritis Rheum 1992; 35: 195–8

    Article  PubMed  CAS  Google Scholar 

  48. Wollenhaupt J, Hammer M, Pott HG, et al. A double-blind, placebo-controlled comparison of 2 weeks versus 4 months treatment with doxycycline in Chlamydia-induced reactive arthritis. Arthritis Rheum 1997; 40: S143

    Article  Google Scholar 

  49. Beutler AM, Hudson AP, Whittum-Hudson JA, et al. Chlamydia trachomaiis can persist in joint tissue after antibiotic treatment in chronic Reiters syndrome/reactive arthritis. J Clin Rheumatol 1997; 3: 125–30

    Article  PubMed  Google Scholar 

  50. Sieper J, Fendler C, Laitko S, et al. No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis. Arthritis Rheum 1999; 42: 1386–96

    Article  PubMed  CAS  Google Scholar 

  51. Toivanen A, Yli-Kerttula T, Luukkainen R, et al. Effect of antimicrobial treatment on chronic reactive arthritis. Clin Exp Rheumatol 1993; 11: 301–7

    PubMed  CAS  Google Scholar 

  52. Yli-Kerttula T, Luukkainen R, Yli-Kerttula U, et al. Effect of a three-month course of ciprofloxacin on the outcome of reactive arthritis. Ann Rheum Dis 2000; 59: 565–70

    Article  PubMed  CAS  Google Scholar 

  53. Wakefield D, McCluskey P, Verma M, et al. Ciprofloxacin treatment does not influence course or relapse rate of reactive arthritis and anterior uveitis. Arthritis Rheum 1999; 42: 1894–7

    Article  PubMed  CAS  Google Scholar 

  54. Sieper J, Braun J. Treatment of reactive arthritis with antibiotics. Br J Rheumatol 1998; 37: 717–20

    Article  PubMed  CAS  Google Scholar 

  55. Toivanen A, Möttönen T. Ankylosing spondylitis: current approaches to treatment. BioDrugs 1998; 10: 193–200

    Article  PubMed  CAS  Google Scholar 

  56. Mielants H, Veys EM. HLA-B27 related arthritis and bowel inflammation. Part 1. Sulphasalazine (Salazopyrin) in HLA-B27 related reactive arthritis. J Rheumatol 1985; 12: 287–93

    CAS  Google Scholar 

  57. Mielants H, Veys EM, Joos R. Sulphasalazine (Salazopyrin) in the treatment of enterogenic reactive synovitis and ankylosing spondylitis with peripheral arthritis. Clin Rheumatol 1986; 5: 80–3

    Article  PubMed  CAS  Google Scholar 

  58. Trnavský K, Pelišková Z, Vácha J. Sulphasalazine in the treatment of reactive arthritis. Scand J Rheumatol 1988; 67: 76–9

    Article  Google Scholar 

  59. Youssef PP, Bertouch JV, Jones PD. Successful treatment of human immunodeficiency virus-associated Reiters syndrome with sulfasalazine. Arthritis Rheum 1992; 35: 723–4

    Article  PubMed  CAS  Google Scholar 

  60. Egsmose C, Hansen TM, Andersen LS, et al. Limited effect of sulphasalazine treatment in reactive arthritis: a randomised double-blind placebo-controlled trial. Ann Rheum Dis 1997; 56: 32–6

    Article  PubMed  CAS  Google Scholar 

  61. Clegg DO, Reda DJ, Abdellatif M. Comparison of sulphasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylar-thropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1999; 42: 2325–9

    Article  PubMed  CAS  Google Scholar 

  62. Breban M, Fournier C, Gougerot-Pocidalo M-A et al. Protective effects of ciprofloxacin against type II collagen induced arthritis in rats. J Rheumatol 1992; 19: 216–22

    PubMed  CAS  Google Scholar 

  63. Toivanen A, Merilahti-Palo R, Gripenberg C, et al. Yersinia-associated arthritis in the rat: experimental model for human reactive arthritis? Acta Pathol Microbiol Immunol Scand (C) 1986; 94: 261–9

    CAS  Google Scholar 

  64. Merilahti-Palo R, Gripenberg-Lerche C, Söderström K-O, et al. Long term follow up of SHR rats with experimental yersinia-associated arthritis. Ann Rheum Dis 1992; 51: 91–6

    Article  PubMed  CAS  Google Scholar 

  65. Zhang Y, Gripenberg-Lerche C, Söderström K-O, et al. Antibiotic prophylaxis and treatment of reactive arthritis. Lessons from an animal model. Arthritis Rheum 1996; 39: 1238–43

    CAS  Google Scholar 

  66. Zhang Y, Toivanen A, Toivanen P. Experimental Yersinia-triggered reactive arthritis; effect of a 3-week course with ciprofloxacin. Br J Rheumatol 1997; 36: 541–6

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The support of a Turku University Central Hospital EVO-grant is gratefully acknowledged.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Auli Toivanen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Toivanen, A. Bacteria-Triggered Reactive Arthritis. Drugs 61, 343–351 (2001). https://doi.org/10.2165/00003495-200161030-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200161030-00003

Keywords

Navigation